Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

• Juliann Chmielecki,
• Jhanelle E. Gray,
• Ying Cheng,
• Yuichiro Ohe,
• Fumio Imamura,
• Byoung Chul Cho,
• Meng-Chih Lin,
• Margarita Majem,
• Riyaz Shah,
• Yuri Rukazenkov,
• Alexander Todd,
• Aleksandra Markovets,
• J. Carl Barrett,
• Ryan J. Hartmaier,
• Suresh S. Ramalingam

Affiliations

Juliann Chmielecki

Translational Medicine, Oncology R&D, AstraZeneca

Jhanelle E. Gray

Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute

Ying Cheng

Jilin Provincial Cancer Hospital

Yuichiro Ohe

Department of Thoracic Oncology, National Cancer Center Hospital

Fumio Imamura

Department of Thoracic Oncology, Osaka International Cancer Institute

Byoung Chul Cho

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

Meng-Chih Lin

Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University

Margarita Majem

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau

Riyaz Shah

Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust

Yuri Rukazenkov

Oncology R&D, AstraZeneca

Alexander Todd

Oncology Biometrics, Oncology R&D, AstraZeneca

Aleksandra Markovets

Translational Medicine, Oncology R&D, AstraZeneca

J. Carl Barrett

Translational Medicine, Oncology R&D, AstraZeneca

Ryan J. Hartmaier

Translational Medicine, Oncology R&D, AstraZeneca

Suresh S. Ramalingam

Winship Cancer Institute, Emory University